Diversify Wealth Management LLC Has $895,000 Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Diversify Wealth Management LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 22.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,759 shares of the company’s stock after acquiring an additional 7,969 shares during the quarter. Diversify Wealth Management LLC’s holdings in Teva Pharmaceutical Industries were worth $895,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Coronation Fund Managers Ltd. bought a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at about $1,334,000. American Century Companies Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 12.9% during the second quarter. American Century Companies Inc. now owns 175,178 shares of the company’s stock worth $2,847,000 after buying an additional 20,026 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Teva Pharmaceutical Industries by 23.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,466,704 shares of the company’s stock valued at $23,834,000 after acquiring an additional 274,891 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 26.7% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 27,643 shares of the company’s stock worth $449,000 after acquiring an additional 5,831 shares in the last quarter. Finally, AE Wealth Management LLC grew its position in Teva Pharmaceutical Industries by 29.0% during the 2nd quarter. AE Wealth Management LLC now owns 198,808 shares of the company’s stock worth $3,231,000 after acquiring an additional 44,718 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $21.97 on Tuesday. The company has a fifty day moving average price of $19.33 and a two-hundred day moving average price of $18.26. The firm has a market capitalization of $24.89 billion, a PE ratio of -25.84, a P/E/G ratio of 1.06 and a beta of 0.73. Teva Pharmaceutical Industries Limited has a 52 week low of $10.86 and a 52 week high of $22.80. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Analysts Set New Price Targets

A number of research firms have commented on TEVA. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.13.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.